

Neutropenia - Pipeline Insight, 2021

<https://marketpublishers.com/r/NC3546251353EN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: NC3546251353EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Neutropenia - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Neutropenia Understanding

Neutropenia: Overview

Neutropenia is a blood condition characterized by low levels of neutrophils, which are white blood cells that protect your body from infections. There are four types of neutropenia: Congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, Idiopathic neutropenia. Neutropenia symptoms can range from mild to severe. The lower the level of neutrophils, the more intense the symptoms. Typical symptoms include: fever, pneumonia, sinus infections, otitis media (ear infection), gingivitis (gum inflammation), omphalitis (navel infection) and skin abscesses. Severe congenital neutropenia can have serious symptoms. The symptoms often include bacterial infections. These infections can grow on the skin and in the digestive and respiratory systems. The symptoms of cyclic neutropenia recur in 3-week cycles. Infections can

increase when neutrophil levels fall. Neutropenia can be triggered by: chemotherapy, radiation therapy, the use of certain drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neutropenia R&D. The therapies under development are focused on novel approaches for Neutropenia.

Neutropenia Emerging Drugs Chapters

This segment of the Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neutropenia Emerging Drugs

Plinabulin: BeyondSpring Pharmaceuticals

Plinabulin, BeyondSpring's lead asset, is a selective immune-modulating microtubule-binding agent (SIMBA). A global Phase 3 clinical trial in CIN (PROTECTIVE-2) with plinabulin in combination with pegfilgrastim versus pegfilgrastim alone has been completed and is the basis for an NDA filing in the U.S. and China for the prevention of CIN. In this trial, plinabulin reduced the "neutropenia vulnerability gap" associated with G-CSF therapy alone.

In March, 2021, BeyondSpring announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and the China National Medical Products Administration (NMPA) for use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN).

Romylocel-L: Cellerant Therapeutics

Romylocel-L, a composition of human myeloid progenitor cells, can be administered to

provide a source of mature neutrophils and provide transient innate immunity until the patient's own immune system recovers.

Romyelocel-L is being developed to prevent bacterial and fungal infections in patients with prolonged neutropenia. Romyelocel-L has been evaluated in three clinical trials to date. In a randomized, controlled Phase 2 trial (NCT02282215), romyelocel-L significantly reduced infections and days in hospital. Romyelocel-L has shown an acceptable safety profile in the three clinical trials, with a total of 151 subjects aged 12 years and above exposed to romyelocel-L.

Further product details are provided in the report

Neutropenia: Therapeutic Assessment

This segment of the report provides insights about the different Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Neutropenia

There are approx. 20+ key companies which are developing the Neutropenia. The companies which have their Neutropenia drug candidates in the most advanced stage, i.e. Preregistration include, BeyondSpring Pharmaceuticals.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neutropenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Neutropenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neutropenia drugs.

Neutropenia Report Insights

Neutropenia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Neutropenia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Neutropenia drugs?

How many Neutropenia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Neutropenia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neutropenia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Neutropenia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tanvex Biopharma

Enzychem Lifesciences

BeyondSpring Pharmaceuticals

Mabwell (Shanghai) Bioscience

Emendo biotherapeutics

Spectrum Pharmaceuticals

Cellerant Therapeutics

X4 Pharmaceuticals

Key Products

TX-04

EC-18

Plinabulin

MW05

EMD-101

Eflapegrastim

Romylocel-L

Mavorixafor

Contents

- Introduction
- Executive Summary
- Neutropenia : Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Neutropenia – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Neutropenia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Neutropenia Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Romylocel-L: Cellerant Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- EC-18: Enzychem Lifesciences
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I)
 - Comparative Analysis
- TX-04: Tanvex Biopharma

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report

Inactive Products
Comparative Analysis
Neutropenia Key Companies
Neutropenia Key Products
Neutropenia- Unmet Needs
Neutropenia- Market Drivers and Barriers
Neutropenia- Future Perspectives and Conclusion
Neutropenia Analyst Views
Neutropenia Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Neutropenia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Neutropenia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Neutropenia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/NC3546251353EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NC3546251353EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970